Savitz Adam 4

What Happened Adam Savitz, Chief Medical Officer of Alto Neuroscience (ANRO), received a derivative equity award on 2026-02-11 covering 124,000 shares. The filing reports an acquisition price of $0.00 and a reported transaction value of $0 (this reflects the award reporting, not necessarily the economic value). This was an equity grant (transaction code A), not a purchase or sale.

Key Details

• Transaction date: 2026-02-11; Form 4 filed: 2026-02-13 (appears timely).
• Reported amount: 124,000 shares; reported price: $0.00; reported cash value: $0 (derivative award).
• Vesting: 25% of shares vest on February 11, 2027; then 1/48th of the shares vest monthly thereafter, subject to continuous service (per footnote).
• Shares owned after the transaction: not specified in the provided filing summary.
• Transaction code: A (grant/award of derivative securities).

Context This was a grant of an equity-based award (an option-style derivative per the vesting footnote), not an exercise or sale. Such awards are commonly part of executive compensation and indicate potential future equity ownership contingent on continued service and vesting; they do not by themselves signal immediate buying or selling.